First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2015-01-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the safety and tolerability of intratracheal administration of two different single doses of CHF 5633 in preterm neonates with RDS in terms of adverse events, adverse drug reactions, hematology and biochemistry values, the incidence of major neonatal morbidities including bronchopulmonary dysplasia (BPD) and mortality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

NCT02452476

Respiratory Distress Syndrome, Newborn

COMPLETED PHASE2

Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease

NCT05898633

Chronic Lung Disease of Prematurity Respiratory Distress Syndrome in Premature Infant Bronchopulmonary Dysplasia

ACTIVE_NOT_RECRUITING PHASE1

The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS

NCT03808402

Respiratory Distress Syndrome Bronchopulmonary Dysplasia

COMPLETED

Human Surfactant Treatment of Respiratory Distress Syndrome Bicenter Trial

NCT00000570

Lung Diseases Respiratory Distress Syndrome

COMPLETED PHASE3

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

NCT06776783

Respiratory Distress Syndrome Pre-term Infants

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be a multicentre, open-label, single escalating dose, per-cohort design.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Distress Syndrome in Premature Infants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Synthetic Surfactant

Cohort Design

Group Type EXPERIMENTAL

synthetic surfactant (CHF5633)

Intervention Type DRUG

CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

synthetic surfactant (CHF5633)

CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent obtained by parents/legal representative (according to local regulation) prior to any study-related procedures
* Inborn and outborn, preterm neonates of either sex with a gestational age of 27 weeks up to 33 weeks+6
* Clinical and radiological findings typical of RDS
* Age on admission to the study \< 24 hours from birth
* Requirement of endotracheal intubation for surfactant administration
* Fraction of inspired oxygen (FiO2) \> 0.35 to maintain SpO2 between 90-95 %
* Documentation of normal cranial ultrasound scan

Exclusion Criteria

* Use of surfactant prior to study entry and need for intratracheal administration of any other treatment (e.g. nitric oxide)
* Known genetic or chromosomal disorders, major congenital anomalies (cardiac malformations, myelomeningocele etc)
* Maternal drug abuse (heroin, methadone, methamphetamine, or cocaine) or significant alcohol consumption during pregnancy
* Clinical chorioamnionitis (Appendix III)
* Strong suspicion of congenital pneumonia/infection, sepsis
* Evidence of severe birth asphyxia or a 5 minutes Apgar score less / equal 3
* Presence of air leaks prior to study entry
* Neonatal seizures prior to study entry
* Mothers with prolonged rupture of the membranes (\> 3 weeks duration)
* Any condition that, in the opinion of the Investigator, would place the neonate at undue risk
* Participation in another clinical trial of any placebo, drug or biological substance conducted under the provisions of a protocol

Minimum Eligible Age

27 Weeks

Maximum Eligible Age

34 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No